Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020.Patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Despite there is a large number of clinical trials of COVID-19 vaccines, only a few participants with chronic liver diseases were included.
This study is a prospective, open-label clinical trial. A total of 300 patients with different cancers including chronic hepatitis, cirrhosis .All of the patients will further accept 18 months follow-up study after vaccination. Safety and immunogenicity will be carefully recorded and detected.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
300
One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
RECRUITINGSafety of coronavirus vaccine
Rate of adverse effects after COVID-19 vaccination
Time frame: Within 2 months after the first dose of COVID-19 vaccination
Immunogenicity of coronavirus vaccine
Detected the dynamics and titers of anti-SARS-CoV-2 antibodies
Time frame: Within 2 months after the first dose of COVID-19 vaccination
Safety of coronavirus vaccine
Rate of adverse effects after COVID-19 vaccination
Time frame: Within 18 months after the first dose of COVID-19 vaccination
Immunogenicity of coronavirus vaccine
Detected the dynamics and titers of anti-SARS-CoV-2 antibodies
Time frame: Within 18 months after the first dose of COVID-19 vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.